Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Innovative Treatment of Cervical Cancer Using Engineered Antigen-specific Immune Effectors (EIEs)

NCT03362619 is registered in ClinicalTrials.gov with Shenzhen Geno-Immune Medical Institute as lead sponsor.

NCT NCT03362619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Innovative Treatment of Cervical Cancer Using Engineered Antigen-specific Immune Effectors (EIEs)
Lead sponsor
Shenzhen Geno-Immune Medical Institute
Phase
Phase 1/2
Overall status
Terminated
Start date
June 1, 2026
Completion date
July 31, 2026
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer